Chengdu Easton Biopharmaceuticals (688513.SH): Methylene blue injection receives FDA drug registration approval in the United States.
Yuandong Biological (688513.SH) announced that its wholly-owned subsidiary, Chengdu Shuode Pharmaceutical Co., Ltd. (referred to as "Shuode Pharmaceutical"), recently received a notice from the U.S. Food and Drug Administration (FDA). Shuode Pharmaceutical's Abbreviated New Drug Application (ANDA) for methylene blue injection, which was submitted to the FDA, has been officially approved.
Chengdu Easton Biopharmaceuticals (688513.SH) announced that its wholly-owned subsidiary Chengdu Shuode Pharmaceuticals Co., Ltd. ("Shuode Pharmaceuticals") recently received notification from the U.S. Food and Drug Administration ("FDA") that its Abbreviated New Drug Application (ANDA) for Methylene Blue Injection has been formally approved.
The active ingredient of Methylene Blue Injection is methylene blue, indicated for the treatment of acquired methemoglobinemia in children and adults.
Related Articles
HUISHANG BANK (03698): Wei Lixiang's qualifications as a non-executive director have been approved for appointment.
Semiconductor Manufacturing International Corporation (00981) issued 16,700 shares in accordance with the 2014 stock incentive plan.
DINGDANG HEALTH (09886) spent HKD 50,100 to repurchase 45,000 shares on December 24th.
HUISHANG BANK (03698): Wei Lixiang's qualifications as a non-executive director have been approved for appointment.
Semiconductor Manufacturing International Corporation (00981) issued 16,700 shares in accordance with the 2014 stock incentive plan.
DINGDANG HEALTH (09886) spent HKD 50,100 to repurchase 45,000 shares on December 24th.
RECOMMEND
